JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Inicio・Lista de Acciones・Denali Therapeutics Inc

Denali Therapeutics Inc

Cerrado

SectorSalud

15.34 -5.37

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

15.09

Máximo

16.25

Métricas clave
By Trading Economics
Ingresos	8.9M -124M
Empleados	486
EBITDA	21M -121M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+101.97% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	348M 2.4B
Apertura anterior	20.71
Cierre anterior	15.34

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

324 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

13.355 / 16.44 Soporte y Resistencia

Denali Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 nov 2025, 21:44 UTC

Ganancias

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov 2025, 23:28 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov 2025, 23:24 UTC

Ganancias

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:14 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

3 nov 2025, 23:14 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov 2025, 23:12 UTC

Ganancias

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov 2025, 23:06 UTC

Charlas de Mercado

Ganancias

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov 2025, 22:36 UTC

Charlas de Mercado

Ganancias

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov 2025, 22:24 UTC

Charlas de Mercado

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov 2025, 21:59 UTC

Charlas de Mercado

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado

Ganancias

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

3 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 nov 2025, 21:49 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov 2025, 21:40 UTC

Ganancias

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov 2025, 21:31 UTC

Charlas de Mercado

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov 2025, 21:19 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov 2025, 21:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov 2025, 21:11 UTC

Ganancias

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov 2025, 21:07 UTC

Ganancias

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov 2025, 21:05 UTC

Ganancias

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:05 UTC

Ganancias

Palantir Technologies 3Q Net $475.6M >PLTR

Comparación entre iguales

Cambio de precio

Denali Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

101.97% repunte

Estimación a 12 meses

Media 32.88 USD 101.97%

Máximo 40 USD

Mínimo 27 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Denali Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Denali Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

13.355 / 16.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimiento

By Acuity

324 / 373 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.